Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up

Creative Commons License

ÇAPKIN E., KARKUCAK M., Kiris A., DURMUŞ İ., KARAMAN K., Karaca A., ...Daha Fazla

RHEUMATOLOGY, cilt.51, sa.5, ss.910-914, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51 Sayı: 5
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1093/rheumatology/ker434
  • Dergi Adı: RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.910-914
  • Anahtar Kelimeler: ankylosing spondylitis, anti-TNF-alpha, pulse wave velocity, arterial stiffness, cardiovascular burden, NECROSIS FACTOR AGENTS, PULSE-WAVE VELOCITY, ANKYLOSING-SPONDYLITIS, ENDOTHELIAL FUNCTION, CARDIOVASCULAR EVENTS, RHEUMATOID-ARTHRITIS, DISEASE-ACTIVITY, INFLIXIMAB, ATHEROSCLEROSIS, INFLAMMATION
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Objective. The availability of new-generation drugs has provided significant success reflected by disease activity markers and clinical status in AS, but controversial reports necessitate further assessment of associated increased risk of cardiovascular burden that might persist. Hence this prospective clinical study evaluated the effectiveness of a 24-week anti-TNF-alpha therapy on vascular stiffness [pulse wave velocity (PWV)] in AS.